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AbsTrACT
Objective To assess whether acetazolamide (Az), used 
prophylactically for acute mountain sickness (AMS), alters 
exercise capacity at high altitude.
Methods Az (500 mg daily) or placebo was administered 
to 20 healthy adults (aged 36±20 years, range 21–77), 
who were paired for age, sex, AMS susceptibility and 
weight, in a double-blind, randomised manner. Participants 
ascended over 5 days to 4559 m, then exercised to 
exhaustion on a bicycle ergometer, while recording breath-
by-breath gas measurements. Comparisons between 
groups and matched pairs were done via Mann-Whitney U 
and Pearson’s χ2 tests, respectively.
results Comparing paired individuals at altitude, those 
on Az had greater reductions in maximum power output 
(P
max
) as a percentage of sea-level values (65±14.1 vs 
76.6±7.4 (placebo); P=0.007), lower VO
2max
 (20.7±5.2 
vs 24.6±5.1 mL/kg/min; P<0.01), smaller changes from 
rest to P
max
 for VO
2
 (9.8±6.2 vs 13.8±4.9 mL/kg/min; 
P=0.04) and lower heart rate at P
max
 (154±25 vs 167±16, 
P<0.01) compared with their placebo-treated partners. 
Correlational analysis (Pearson’s) indicated that with 
increasing age P
max
 (r=−0.83: P<0.005) and heart rate at 
P
max
 (r=−0.71, P=0.01) reduced more in those taking Az.
Conclusion Maximum exercise performance at altitude 
was reduced more in subjects taking Az compared with 
placebo, particularly in older individuals. The age-related 
effect may reflect higher tissue concentrations of Az due to 
reduced renal excretion. Future studies should explore the 
effectiveness of smaller Az doses (eg, 250 mg daily or less) 
in older individuals to optimise the altitude–Az–exercise 
relationships.
InTrOduCTIOn
Acetazolamide (Az) is an important medica-
tion for the prevention of acute mountain 
sickness (AMS). This was demonstrated 
initially by Forwand et al,1 followed by a large 
study on Everest trekkers,2 with an accom-
panying editorial.3 In controlled studies, Az 
has been shown to increase arterial oxygen 
saturations at all altitudes and to assist in 
ascents to Everest Base Camp, the summit of 
Kilimanjaro and elsewhere.4–6 A meta-anal-
ysis of 24 placebo-controlled trials comparing 
1011 Az-treated with 854 placebo-treated 
individuals showed convincing evidence of 
its value for the prevention of AMS.7 Esca-
lating doses of Az from 250 mg to 500 mg and 
750 mg per day reduced AMS relative risk by 
45%, 50%, and 55% respectively, although 
current recommendations suggest 125 mg 
twice daily.
An important but controversial aspect of 
Az use is its effect on exercise at altitude. Five 
chamber studies examining the impact of Az 
during short-term exposure to hypoxia, three 
of these showed reduced VO
2max
 and/or 
time to exhaustion,8–10 one a slight increase 
in VO
2max
,11 and one no effect.12 Similar 
inconsistent findings have been reported in 
natural high-altitude environments. Hackett 
et al13 gave Az acutely to well-acclimatised 
individuals and observed a reduction in 
exercise performance (time at maximum 
workload), whereas Faoro et al14 observed no 
effect. Results are again inconsistent when 
Az is used prophylactically. Specifically, after 
a 14-day trek to 4846 m, VO
2max
 and exercise 
endurance were greater on Az compared with 
placebo.15 Conversely, when used during early 
acclimatisation (18–24 hours), Az reduced 
exercise performance, but only in individuals 
over 50 years of age.16
Key messages
What are the new findings?
 ► Acetazolamide (Az) decreased maximum power 
output at 4559 m.
 ► Effects of Az were greater in those over 50 years 
of age.
 ► Doses of Az may need to be optimised especially in 
older subjects to minimise adverse effects.
How might it impact on clinical practice in the 
near future?
 ► Findings indicate that smaller doses of Az may be 
more appropriate for older individuals visiting and 
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Surveys of trekkers add no further information, despite 
Az being widely used with no reported adverse effects on 
exercise. For instance, on Kilimanjaro, 35% of climbers 
use Az yet the overall summit success rate can be as low 
as 50%–60% during ascents over 3 and 4 days. Those 
affected by Az might ascend more slowly and ascribe any 
perceived weakness to altitude or poor fitness. Neverthe-
less, exercise capability is an important issue when there 
are time-restricted climbing schedules or in some emer-
gency situations. There are also questions about the use 
of Az in older individuals. Az is excreted unmetabolised 
in urine,17 18 so drug levels increase in line with reduced 
glomerular filtration rates (GFR). Given the known 
age-related decline in renal function, Az concentrations 
might increase sufficiently to induce excess acidosis in 
older individuals, thereby inhibiting exercise. Given that 
increasing numbers of older people are exploring high 
mountains,19 questions regarding the effect of Az on exer-
cise need to be answered, particularly as older people may 
be less susceptible to AMS.20 Against this background the 
purpose of the current study was to assess the effects of Az 
on exercise performance in young and older individuals 
during a typical alpine high-altitude climb.
MeTHOds
subjects
Twenty healthy individuals were recruited (16 male), 
mean age 36 years (range 21–77 years): 13 were under 
26 years and 6 were males over 50 years. Fifteen individ-
uals had previous experience of high altitude allowing 
their self-reported susceptibility to AMS to be categorised 
into mild or moderate, but no participant had suffered 
from high-altitude pulmonary or cerebral oedema. 
All subjects had resided below 1500 m in the previous 
2 months, none were taking medication affecting the 
cardiovascular system, all were non-smokers and no 
intense physical activity had been undertaken for 7 days 
before baseline testing. All participants had free access to 
fluids during the studies, but no formal measurements of 
hydration status or urine volumes were undertaken.
Individuals were paired for similar characteristics 
according to the following hierarchy: (1) age, (2) sex, (3) 
previous AMS susceptibility and (4) body mass (table 1). 
Each member of the pairs was randomised to Az 250 mg 
twice daily or placebo (lactose powder), in identical 
capsule form, following a double-blind design. Medica-
tion was started the day before altitude exposure and 
continued for a total of 10 doses over 5 days. Because of 
potential unblinding linked to Az side effects, individuals 
were requested not to discuss any aspects of their medi-
cation.
baseline experiments and equipment
Two weeks before ascent, graded baseline exercise tests 
were carried out in Birmingham (150 m above sea-level) 
to determine maximum power output (P
max
) and 
maximum oxygen uptake (VO
2max
). Exercise tests were 
performed on a light-weight (25 kg), recumbent bicycle 
ergometer designed for altitude studies (Alticycle) as 
previously described.16
After a 5 min, self-paced warm-up, participants 
commenced at 50–100 W depending on their self-re-
ported level of fitness. Using a cadence of 60 rev/min, 
power was increased every 3 min by 25 W or 15 W, for 
men or women, respectively, until 80% of the predicted 
maximum. Thereafter, power steps were increased 
every minute until volitional exhaustion. Breath-by-
breath gas measurements were recorded of minute 
ventilation (VE), end-tidal oxygen (PetO
2
) and carbon 
dioxide (PetCO
2
) concentrations, oxygen uptake 
(VO
2
) and expired CO
2
 (VCO
2
) using a Cosmed K4b2 
(Cosmed, Rome, Italy).21 Heart rate (HR), peripheral 
blood O
2
 saturations (SpO
2
) and perceived exertion 
were recorded at rest and for every exercise stage. The 
maximum VO
2
 attained (VO
2max
) was determined as the 
highest 20 s moving average in VO
2
, together with the 
corresponding P
max
.
Baseline serum creatinine measurements were used 
to estimate GFR (eGFR) using the Cockcroft-Gault 
equation.22
Table 1 Participant characteristics (mean±SD) at baseline (150 m)
Placebo (10) Acetazolamide (10)
Sex: male/female 8/2 8/2
Age (range of years) 33±17 (21−66) 40±23 (21−77)
Height (cm) 176±8 (159–185) 177±11 (154−189)
Weight (kg) 73±13.6 (46.7–91.2) 73±13 (48.1–91.8)
AMS history: mild:moderate:unknown 3:4:3 6:2:2
VO
2max
 (mL/kg/min) 40.3±6.3 (29.3–47.7) 35.9±6.1 (26.9–44.4)
Maximum power output (W) 234±51 (155−305) 215±39 (155−260)
Heart rate maximum (beats/min) 185±20 (150−208) 169±26 (122−198)
Peak respiratory exchange rate 1.11±0.2 (0.7–1.3) 1.16±0.05 (1.1–1.2)
*There were no significant differences (all P>0.05) between groups (Mann-Whitney U test).
AMS, acute mountain sickness.
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Ascent profile and altitude studies
Individuals travelled by sea and overland from the UK 
to Gressonay (1640 m) in Italy over an 18-hour period, 
followed by a 2-night stay that included an acclimati-
sation ascent to 2800 m. Participants ascended in two 
groups on consecutive days to 2646 m, 3647 m and 
4559 m at the Margherita Hut, which involved 3–5 hours 
of moderate to strenuous exercise daily. Matched pairs 
ascended together. Self-assessed questionnaires using 
the Lake Louise (LL) scoring system for AMS23 were 
recorded morning and evening to produce twice daily 
AMS scores. At the Margherita Hut (4559 m), individ-
uals were tested on the exercise bicycle between 2 and 
10 hours after arrival, with matched pairs being assessed 
within 90 min of each other. Exercise tests at high alti-
tude were performed in a similar manner, using the same 
incremental steps as baseline, but at 40% less power in 
accordance with a previous report of power reduction at 
altitude.24 Individuals were asked after their exercise test 
which medication they thought they were taking.
Analysis of results and statistics
Comparisons of Az and placebo groups were made for 
reduction of maximum power from baseline to alti-
tude. In addition, changes in altitude performance were 
compared between the groups, and between Az/placebo 
treatments within paired individuals. Statistical analyses 
were performed using SPSS V.21. Mann-Whitney U test 
was used to analyse differences of means; Pearson’s χ2 
test was used to analyse observed differences between 
matched pairs; Pearson’s correlation was used to test the 
relationship between variables of interest (age vs HR
max
). 
Results are given as mean±SD throughout, and results 
reaching P<0.05 were considered significant. No a priori 
decisions were made regarding the effects of Az on any 
variable.
resulTs
baseline studies
Baseline measures are shown in table 1. There were no 
significant differences between placebo and Az groups.
exercise test
Results are shown in table 2 and figures 1–3. At rest, 
VO
2
, VCO
2
 and respiratory exchange ratios were similar 
between groups, while resting SpO
2
 and PetO
2
 were 
higher and PetCO
2
 was lower in the Az-treated group 
compared with the placebo-treated group.
During exercise at altitude, all participants were able 
to achieve 45% of their baseline performance, but at 
higher power, there was progressive failure until only one 
individual in each group was able to perform at 90% of 
baseline P
max
 (figure 1). At 45% of baseline performance, 
VE and PetO
2
 were on average higher, while PetCO
2
 was 
lower in the Az group compared with the placebo group 
(table 2). Greater maximum power was generated by 
placebo participants, both as a group (P=0.03) (figure 1) 
and in the matched pairs (P=0.007) (table 2). VO
2max
 
was higher in the placebo group within the matched 
pairs (P=0.0003), but as a whole group, the difference 
did not reach significance (P=0.063). VCO
2
 was higher 
on placebo at maximum performance both as a group 
and in the matched pairs (table 2). While resting HRs 
were not different between groups, those on Az had 
lower HR at P
max
 compared their placebo-matched pair 
(figure 2).
Correlation analysis of the matched pairs was used to 
assess the relationship between age and the effect of Az 
on exercise parameters at altitude. With increasing age 
of the matched pairs, there was a greater reduction in 
HR
max
 on those taking Az compared with their placebo 
partners (r=−0.71, P=0.01; figure 3A). Similarly, there was 
a greater reduction in P
max
 from baseline performance in 
those taking Az (r=−0.83: P<0.005; figure 3B). There was 
a negative correlation between baseline eGFR of partici-
pants and their age (r=−0.69; P=0.001).
Figure 1 Numbers of individuals taking placebo or 
acetazolamide (Az) completing each exercise stage (ranging 
from 23% to 90% of baseline values) at 4559 m. For 
example, at 68% of baseline power, the test was completed 
by three Az and nine placebo individuals. P=0.03 by Mann-
Whitney U test for differences of means.
Figure 2 Studies at 4559 m showing maximum heart rate 
(HR) for the matched pairs of participants. Pairs <50 years 
are shown as solid lines and >50 years are shown as dotted 
lines. Pearson’s χ2 test for observed differences between 
matched pairs at altitude.
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Questionnaires recorded immediately after the exer-
cise test indicated that 11 had correctly guessed their 
medication (eight on Az and three on placebo), seven 
did not know (two on Az and five on placebo), while two 
on placebo thought they were taking Az. On the day of 
the exercise test, the mean of the summated morning 
and evening LL AMS scores were similar in the two 
groups (Az vs placebo: 2.1±2.0 vs 2.1±1.3, P=0.7). Only 
two individuals had scores over 3 on the exercise test day, 
one in the placebo group and one in the Az group, both 
of whom completed the exercise test satisfactorily.
dIsCussIOn
Main findings
The main finding of this study was the greater reduction 
in P
max
 at altitude in individuals taking Az compared 
with those on placebo, particularly in those over 50 years 
old. Despite the stimulation of respiratory centres by Az, 
leading to higher SpO
2
 and PetO
2
 at rest, this did not 
translate into an improvement in exercise performance. 
Indeed, during the incremental increases in exercise 
intensity, the fall in SpO
2
 was greater in the Az group. 
In contrast, VO
2
 and VCO
2
 showed larger increases in 
the placebo group, indicating a greater exercise capacity. 
At altitude, resting HRs were similar in both groups, but 
at P
max
 Az-treated participants showed smaller increases 
from baseline. This was apparent in the matched pairs 
and more so in individuals over 50 years.
Previous studies
Our finding of impaired P
max
 in subjects on Az is consis-
tent with our previous study at lower altitude (3459 m), 
which did not use a progressive exercise test to P
max
 or 
examine detailed metabolic data.16 It is also consistent 
with a detailed chamber study at a simulated altitude of 
4200 m.10 The latter study reported reduced blood pH at 
near-peak exercise on Az. Such pH changes reflect the 
slowed CO
2
 excretion kinetics and the renal-metabolic 
acidosis mediated by Az, via inhibition of carbonic anhy-
drases (CA).25
Field-based studies at altitude previously reported have 
produced conflicting results. Comparison is difficult 
because studies were undertaken at different altitudes, 
using different Az doses and with a variety of ascent 
profiles. In particular, larger doses are likely to have the 
greatest inhibiting effect on exercise ability, as shown in 
the data of Garske et al,10 who used 1000 mg per day for 
2.5 days prior to testing. Since Az has a half-life of 8–12 
hours,26 it would accumulate to produce a greater effect 
in those taking the drug for several days, rather than only 
24 hours (as frequently used in chamber studies). Field-
based studies have generally been over longer periods 
and in individuals who were acclimatised. We chose to 
study the effect of Az during early acclimatisation, which 
is pertinent to the ascent of mountains such as Mt Blanc 
and Kilimanjaro.
Mechanism of action of Az
The mechanism of action of Az has been widely studied.27 
Multiple effects include a metabolic acidosis when suffi-
cient bicarbonate has been excreted, which typically takes 
24 hours or more.28 At altitude, this provides a beneficial 
ventilatory stimulus that opposes and limits the braking 
effect of hypocapnia on the full ventilatory response 
to hypoxia. However, CA isoenzymes are widespread 
throughout the body including the heart. The heart has 
high concentrations of the CA-IV isoenzyme, which is 3.5 
times more sensitive to Az inhibition than CA-II (wide-
spread in tissues) and is threefold more enzymatically 
active.29 This suggests important cardiac functionality.30 
Indeed, we observed that HR failed to increase as much in 
the Az group during exercise, particularly in older partic-
ipants where Az retention may have been higher due to 
age-related changes in renal function (discussed below). 
Skeletal muscle, however, contains predominantly CA-III, 
which is minimally inhibited by Az.31 However, other 
factors should also be considered in relation to impaired 
exercise performance in hypoxia, especially the role of 
the central nervous system. In particular, altitude alters 
autonomic nervous system functions, which are thought 
Figure 3 Studies on paired participants (placebo vs acetazolamide (Az)) for P
max
 at altitude showing (A) the relationship 
between mean age of each pair and within pair differences for maximum heart rate (HR
max
), and similarly for (B) mean age of 
each pair and differences in reduction in maximum power (P
max
) from baseline (Pearson’s correlation).
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to play an important role in the regulation of cardiac 
output and ventilation.32
Older people
The greater effect of Az on exercise performance in 
older people raises important questions regarding 
dosage, especially given the increasing numbers of 
older people trekking at altitude.19 Since Az is largely 
excreted unchanged in urine (90% of an oral dose is 
excreted within 24 hours) and GFR decreases with age, 
tissue concentrations may be higher in older people. For 
example, toxicity is frequently observed when Az is used 
for treating glaucoma, a disease of older people. In partic-
ular, patients with reduced GFR or who are on dialysis 
are prescribed doses of 125 mg per day or less.18 In such 
patients, fatigue and lethargy are well-known side effects, 
but there are no studies of exercise performance in this 
group. Conventionally, Az usage at altitude is perceived as 
having few consequential side effects, which are limited 
to taste disturbance and paraesthesia. However, there are 
concerns about the optimal dosage, which is currently 
recommended as 125 mg twice daily. Our data provide 
evidence that this may not be appropriate under all 
circumstances. The optimum therapeutic dose of Az may 
have to be individualised for the prophylaxis of AMS.7 
Higher dosing schedules may provide additional benefits 
by reducing the risk of AMS, but this could be offset by 
reduced exercise performance. Studies of doses as low as 
125 mg per day in older people are required with assess-
ments of AMS scores, peripheral oxygen saturations, 
exercise performance and accompanied by measure-
ment of blood concentrations of Az to fully address this 
question. Nevertheless, our results are consistent with 
the current recommendations on the dose of Az used 
for prophylaxis of AMS and indicate that Az would not 
enhance exercise performance if taken by healthy indi-
viduals at altitude and, indeed, might have the opposite 
effect at maximum effort.
limitations
We acknowledge that a VO
2max
 test is only one measure 
of performance, and other determinants of exercise 
performance and capacity at high altitude, such as endur-
ance, may be relevant in this context. Further our study 
contained only 20 individuals, so was relatively low-pow-
ered statistically, particularly for older participants. We 
used a matched-paired design to address this low power 
issue. While an alternative crossover study would improve 
this further, such a design is difficult to achieve in the 
field. In common with most reported studies, blood 
concentrations of Az were not measured, which could 
have provided direct evidence of an age effect. Since Az 
is a mild diuretic, dehydration may have contributed to 
reductions in exercise performance in this group. In a 
carefully controlled hypobaric chamber study, in which 
a reduction of 4% body weight was achieved, resulted in 
8% reduction in maximum exercise performance.33 We 
did not measure hydration status, but we do not believe 
our subjects were dehydrated to that extent, as they had 
free access to fluids. Hydration would be worth assessing 
in future studies of exercise at high-altitude exercise. 
Further work is required to establish more clearly the 
effect of Az on exercise performance and the possible 
effects of age and perhaps gender.34
COnClusIOn
During an alpine ascent to 4559 m over 5 days, Az 500 mg 
daily reduced maximum exercise capacity, particularly 
in older people. Compared with individuals on placebo, 
those on Az had reduced O
2
 uptake and CO
2
 production 
at P
max
. The greater effect of Az on exercise performance 
in older people may have reflected relative overdosage 
due to age-related reduction in renal clearance. While 
Az has value in preventing AMS, age-appropriate dosage 
may be necessary to compensate for age-related changes 
in Az clearance.
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